ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Final Results of the Phase II RE-ExPEL Study: Ramucirumab Beyond Progression + TAS 102 in Advanced/Metastatic Adenocarcinoma of the Stomach or GEJ, After Treatment Failure on a Ramucirumab-Based Therapy
By
ASCO GI 2023 Conference Coverage
FEATURING
Thorsten Oliver Götze
By
ASCO GI 2023 Conference Coverage
FEATURING
Thorsten Oliver Götze
162 views
January 31, 2023
Login to view comments.
Click here to Login
Videos